November 5, 2020 7:56am

SELL, realize gains and take some profit off the table; political and legal battles over the presidency are far from over; even when results are solidified, legal recriminations will continue

Pre-open indications: 13 SELLs into Strength

News: Earnings releases continue, Sage Therapeutics (SAGE) and Intellia Therapeutics (NTLA)

What I provide is an “intelligence daily” to ensure that shareholders are kept apprised based on a 24-hour surveillance of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  My gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times

Dow futures are UP +1.41% (+390 points), S&P futures are UP +1.83% (+63 points) and NASDAQ futures are UP +2.58% (+303 points)

 

U.S. stock index futures were higher in early morning trading on Thursday;

European stocks advanced as the pan-European Stoxx 600 climbed +0.9% in early trade;

Asia-Pacific stocks were higher with MSCI’s broadest index of Asia-Pacific shares outside Japan rising +2.38%.

 

Henry’omics:

Markets are feeling a tailwind as some of the political anticipation has been overcome.

The question remains of how to find certainties from and in uncertain times?

A lingering issue is the uptick in coronavirus infections …

 

Wednesday night’s post: RegMed Investors’ (RMi) closing bell: “wow, momentum rolls sector skyward; election outlook, still on hold; expectation could have major consequences for markets”

  • The Nasdaq closed UP +430.21 points (+3.85%);
  • The IBB closed up +6.04% and XBI closed up +6.16%
  • Sector volume was the usual LOW with 15 of the 28-upside having higher than the 3-month average volume with the increased volume of 2 of 4-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -5.98 points or -16.82% at 29.57;
  • Wednesday’s percentage (%) of the 28-upside were +0.63% (CLBS) to +14.61% (GBT) while the 4-downside ranges from -1.86% (BCLI) to -6.67% (BLCM);

Q4’s: November, so far: 3 positive closes

  • Q4’s October: 1 neutral, 11 positive and 10 negative closes
  • Q3: July through September: 1 neutral, 28 positive and 34 negative closes with 2 holidays

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed flat at $1.47 after Tuesday’s +$0.09 to $1.47 with 450 shares traded after Monday’s flat at $1.38 with 102 shares traded, Friday’s +$0.02 to $1.38 with 523 shares traded and last Thursday’s flat at $1.35 (after being up +$0.14 with pricing erosion with 16,972 shares traded – 3-month average = 5058 shares).

  • Question#1: WHO is signing the 10-Q, a part-time hired hand?
  • Question#2: WHY won’t the current officers sign?

 

SELL into Strength:

Alnylam Pharmaceuticals (ALNY) closed up +$10.44;

BioLife Solutions (BLFS) closed up +$1.08;

bluebird bio (BLUE) closed up +$4.00 but, has a NEGATIVE -$6.84 or -11.68% aftermarket indication following earnings release;

CRISPR Therapeutics (CRSP) closed up +$8.69;

Editas Medicine (EDIT) closed up +$2.14 and has a NEGATIVE -$0.15 or -0.49% aftermarket indication;

Fate Therapeutics (FATE) closed up +$4.25 with a POSITIVE +$0.32 or +0.64% aftermarket indication;

Global Blood Therapeutics (GBT) closed up +$7.89 and has a POSITIVE +$0.17 or +0.27% aftermarket indication;

Intellia Therapeutics (NTLA) closed up +$1.90;

Regenxbio (RGNX) closed up +$2.37;

uniQure NV (QURE) called up +$2.60;

Ultragenyx (RARE) closed up +$11.53 with a NEGATIVE -$1.09 or -0.96%;

Sage Therapeutics (SAGE) closed up +$4.32;

 

The BOTTOM LINE: I am troubled by this market; the equity balloon is stretched …today is STILL a wait and see opportunity and the Nasdaq continues to boom.

A quote from another, ““The race is closer than the market thought,” said Patrick Bennett, a strategist at Canadian Imperial Bank of Commerce. “Reflation is one thing, but a close result - and we are far from the end - is a market negative.”

Now we enter the big upswing in sector earnings’ LPS (loss-per-share) releases with the next month likely to remain volatile and uncertain.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.